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ABSTRACT 28 
Background. Carotid artery (CCA) dilation occurs in healthy subjects during cold pressor 29 
test (CPT), whilst the magnitude of dilation relates to cardiovascular risk. To further explore 30 
this phenomena and mechanism, we examined carotid artery responses to different 31 
sympathetic tests, with and without α1-receptor blockade, and assessed similarity to these 32 
responses between carotid and coronary arteries. 33 
Methods. In randomised order, 10 healthy participants (25±3 yrs) underwent sympathetic 34 
stimulation using the CPT (3-minutes left hand immersion in ice-slush) and lower-body 35 
negative pressure (LBNP). Before and during sympathetic tests, CCA diameter and velocity 36 
(Doppler ultrasound) and left anterior descending (LAD) coronary artery velocity 37 
(echocardiography) were recorded across 3-min. Measures were repeated 90-min following 38 
selective α1-receptor blockade via oral Prazosin (0.05mg per kg bodyweight).   39 
Results. CPT significantly increased CCA diameter, LAD maximal velocity and velocity-40 
time integral area-under-the-curve (all P<0.05). In contrast, LBNP resulted in a decrease in 41 
CCA diameter, LAD maximal velocity and velocity time integral (VTI, all P<0.05). 42 
Following α1-receptor blockade, CCA and LAD velocity responses to CPT were diminished. 43 
In contrast, during LBNP (-30mmHg), α1-receptor blockade did not alter CCA or LAD 44 
responses. Finally, changes in CCA diameter and LAD VTI-responses to sympathetic 45 
stimulation were positively correlated (r=0.66, P<0.01). 46 
Conclusion. We found distinct carotid artery responses to different tests of sympathetic 47 
stimulation, where α1-receptors partly contribute to CPT-induced responses. Finally, we found 48 
agreement between carotid and coronary artery responses. These data indicate similarity 49 
between carotid and coronary responses to sympathetic tests and the role of α1-receptors that 50 
is dependent on the nature of the sympathetic challenge.  51 
 52 
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NEWS AND NOTEWORTHY 55 
 56 
 We showed distinct carotid artery responses to cold pressor test (i.e. dilation) and 57 
lower-body negative pressure (i.e. constriction). 58 
 Blockade of α1-receptors significantly attenuated dilator responses in carotid and 59 
coronary arteries during CPT, whilst no changes were found during LBNP.  60 
 Our findings indicate strong similarity between carotid and coronary artery responses 61 
to distinct sympathetic stimuli, and for the role of α-receptors.  62 
ABBREVIATION LIST 63 
 64 
Cardiovascular disease (CVD) 65 
Cardiac output (CO) 66 
Cold pressor test (CPT) 67 
Common carotid artery (CCA) 68 
Diastolic blood pressure (DBP) 69 
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INTRODUCTION 82 
Activation of the sympathetic nervous system (SNS) is an important and clinically-relevant 83 
prognostic stimulus to examine artery function (12, 36). During the cold pressor test (CPT), a 84 
potent sympathetic stimulus, the coronary arteries can result in a vasoconstrictor (via α1-85 
receptors) or vasodilatory response (via the α2-, and β-receptors)(2). Vasodilator pathways 86 
prevail in healthy volunteers (10, 27), whereas experimental studies in patients with coronary 87 
artery disease demonstrate vasoconstriction during SNS activation (30, 47, 49). Coronary 88 
artery responses to CPT independently predict future cardiovascular events in patients at risk 89 
for cardiovascular disease (31, 32, 36), which highlights the clinical relevance of this 90 
response. However, the invasive nature of angiography make these tests impractical for large 91 
scale clinical use. Interestingly, the carotid artery shows vasodilation during SNS activation in 92 
healthy subjects, similar to coronary artery responses. This carotid dilation is abolished or 93 
even reversed to vasoconstriction in those with (increased risk for) cardiovascular disease (34, 94 
44). To date, relatively little is known about the underlying mechanisms for the carotid artery 95 
reactivity to SNS activation.  96 
 97 
Previous studies in peripheral conduit arteries have reported divergent responses to different 98 
tests of SNS-activation (11, 15, 25, 27, 41). To date, no previous study compared vasomotor 99 
responses of the carotid artery to distinct SNS stimuli. In line with peripheral arteries (i.e., the 100 
brachial and superficial femoral artery), we expect that distinct SNS stimuli (i.e. CPT and 101 
lower body negative pressure (LBNP)) lead to distinct carotid and coronary artery responses, 102 
as these tests mediate sympathetic activation through different pathways. More specifically, 103 
CPT evokes sympathetic activation via cold stress. The LBNP test gradually decreases central 104 
blood volume which results in progressive increases in muscle sympathetic nerve activity (8, 105 
9), which can directly lead to constriction of the carotid diameter.  106 
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No previous study examined the potential underlying mechanisms mediating carotid artery 107 
vasomotion during SNS activation. Work in both animal and human coronary arteries 108 
revealed a central role for α1-receptors to mediate vasomotor responses during SNS activation 109 
(17, 23, 26). In line with this previous work, we expect that α1-receptors, at least in part, 110 
contribute to the carotid artery responses to CPT and LBNP. Therefore, our first aim is to 111 
examine the impact of activation of the SNS, either through the CPT (i.e. elevates SNS 112 
activity and blood pressure)(18, 46) or LBNP (i.e. elevates SNS activity, with preserved blood 113 
pressure)(21, 45) on carotid artery diameter. Our second aim was to assess the role of α1-114 
adrenoreceptors to these carotid artery responses by using an oral, selective α1-adrenoreceptor 115 
blocker (i.e. Prazosin).  116 
 117 
A recent study found good agreement between carotid and coronary responses to the CPT in 118 
healthy young and older subjects (44). To further explore this relationship, we aimed to 119 
compare the responses between the carotid artery diameter and left anterior descending 120 
coronary artery velocity (LAD velocity) during different SNS stimuli, with and without α1-121 
receptor blockade. Based on previous work (34, 44), we anticipated that there would be 122 
similarity in the magnitude and direction of the vascular responses between both the carotid 123 
artery diameter and LAD velocity, and that these responses would be partly mediated via α1-124 
receptors.  125 
 126 
METHODS 127 
Ethical approval 128 
This study was approved by the Human Ethics Committee of the University of British 129 
Columbia and conformed to the standards set by the Declaration of Helsinki. All volunteers 130 
provided written informed consent. 131 
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 132 
Participants 133 
We recruited 10 healthy male participants (mean age 25±3 years, height 1.78±0.1 m, and 134 
weight 76±9 kg). Exclusion criteria were a history of cardiovascular disease (i.e. angina 135 
pectoris, myocardial infarction, heart failure), lung disease (i.e. COPD, lung cancer), brain 136 
disease (i.e. stroke, dementia), presence of Raynaud's phenomenon, scleroderma, chronic pain 137 
and/or open wounds on the upper extremities, obesity (body mass index >30 kg/m
2
), diabetes 138 
mellitus type 1 or 2, history of smoking, or elevated blood pressure (systolic >130 mmHg; 139 
diastolic >85 mmHg).  140 
 141 
Experimental design 142 
All participants reported to our laboratory for a single visit. They were asked to abstain from 143 
strenuous exercise for 24 hours and abstain from dietary products known to affect endothelial 144 
function for ≥18 hours prior to the testing session (i.e. vitamin C, caffeine and alcohol). 145 
Moreover, participants were asked to fast for ≥2 hours, adapted from existing guidelines to 146 
assess peripheral vascular function (38). Participants rested in the supine position for >15 147 
minutes on a bed in a temperature-controlled room (23±1°C). Subsequently, participants 148 
underwent LBNP and two CPT, in a randomly assigned order, with 45-minutes rest between 149 
tests. All tests involved simultaneous assessment of common carotid artery (CCA) diameter 150 
and velocity (ultrasound) and left anterior descending (LAD) coronary artery velocity 151 
(echocardiography) before (across a 1-minute baseline) and during sympathetic stimulation. 152 
The protocol was repeated 90-minutes after oral administration of Prazosin (i.e. α1- adrenergic 153 
receptor antagonist that effectively blocks 80% of α1-recepter activity, 0.05mg per kg body 154 
weight)(1, 22). 155 
 156 
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Experimental measures  157 
Common carotid artery diameter and velocity. Left carotid artery diameter and red blood cell 158 
velocity were recorded simultaneously and continuously during baseline (1-minute) and 159 
sympathetic stimuli (i.e. 3-minutes CPT, and ~18-minutes LBNP). Carotid artery image 160 
acquisition was performed using a 10-MHz multifrenquency linear array handheld probe 161 
attached to a high resolution ultrasound machine (15L4, Terason T3200, Burlington, MA, 162 
USA). When an optimal image was found, 2-3 cm proximal from the bifurcation, the probe 163 
was held stable and the ultrasound parameters were set to optimise the longitudinal, B-mode 164 
image of the lumen-arterial wall interface. Continuous pulsed wave Doppler velocity 165 
assessments were also obtained and were collected at the lowest possible insonation angle 166 
(always <60º). Assessment was performed by an experienced sonographer (ACCM), whom 167 
has an hour-to-hour reproducibility (i.e. coefficient of variation) of CCA baseline diameter of 168 
0.8% and reproducibility of 0.8% for the peak CCA diameter, in line with previous findings 169 
(44). 170 
 171 
Coronary artery velocity. Before and during both CPT and LBNP, the left anterior descending 172 
(LAD, cm) coronary artery velocity was examined using transthoracic ultrasound. This 173 
assessment was performed simultaneously with CCA diameter and velocity responses. All 174 
echocardiographic measurements were collected by a trained sonographer (MS) on a 175 
commercially available ultrasound system (Vivid E9; GE, Fairfield, CT) using a broadband 176 
M5S 5 MHz or a 3V 3D-array transducer. In a previous study the Cronbach's alpha reliability 177 
test revealed alpha values of 0.81 and 0.89 for both max and mean LAD velocities, 178 
respectively, suggesting good consistency between LAD velocity measurements (5). 179 
Participants assumed a left lateral position to allow for data collection. The LAD was imaged 180 
using a modified parasternal short axis view from the fourth or fifth left intercostal space, and 181 
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was assessed using pulsed-wave Doppler. The transducer was positioned such that a 2- to 3-182 
mm segment of the LAD was imaged along the long axis, taking care to align the pulse-wave 183 
cursor with the length of the vessel. With a sample volume (2.0 mm) positioned over the color 184 
Doppler signal in the LAD, measurements of the LAD velocity were collected during the 185 
sympathetic tests.  186 
 187 
Blood pressure and heart rate. All continuously recorded cardiovascular measurements were 188 
acquired at 200 Hz using an analog-to-digital converter (Powerlab/16SP ML 880; 189 
ADInstruments, Colorado Springs, CO, USA) interfaced with a personal computer. Before 190 
and during CPT and LBNP, systolic and diastolic blood pressure (SBP and DBP, in mmHg, 191 
respectively), stroke volume (SV, ml), rate-pressure product (RPP, HR x SBP, a reliable 192 
indicator for myocardial oxygen demand)(14), and cardiac output (CO, L/min) were 193 
continuously measured using non-invasive finger photoplethysmography (Finometer Pro, 194 
Finapres medical systems, Amsterdam, Netherlands). Heart rate (HR, beats per minute) was 195 
recorded using three-lead electrocardiography, placed in lead II configuration (Bioamp, 196 
ML132, ADInstruments, Colorado Springs, CO, USA).  197 
 198 
 Sympathetic stimuli 199 
Cold pressor test. The cold pressor tests (CPT) consisted of a 3-minute immersion of the left 200 
hand in a bucket of ice slush (~4.0°C)(44). The participant was positioned in supine position 201 
on a tilt bed, tilted slightly to the left lateral position (~25-30°), to facilitate arm movement in 202 
the bucket of slush without significant movement of the body, and provide adequate coronary 203 
assessment. After a 1-minute baseline period, the participants hand was immersed up to the 204 
wrist in the ice-slush for 3 minutes. The participant was instructed to remain quiet during the 205 
CPT to provide for valid CCA assessment. The partial pressures of end-tidal carbon dioxide 206 
van Mil et al.  SNS activation & central artery responses 
(PETCO2) and oxygen (PETO2) were clamped at baseline values for the entire duration of the 207 
protocol to reduce the potential impact of hyperventilation on the vascular responses, upon an 208 
end-tidal forcing approach described extensively elsewhere (43). To reduce measurement 209 
error, CPT procedures were repeated twice and averaged for analyses (44). 210 
 211 
Lower body negative pressure. The participant was positioned in the supine position on a tilt 212 
bed, and strapped into a custom-made airtight, lower-body suction chamber at the level of the 213 
iliac crest (42). The LBNP chamber was then moved from supine position into a left lateral 214 
position (~25-30°) to ensure adequate coronary imaging. The lower body negative pressure 215 
test consisted of a 5-minute baseline, followed by progressive 2-minute stages, using 216 
increments of -10 mmHg, to -80 mmHg or until pre-syncope. LBNP was terminated when a) 217 
pre-syncope occurred, defined by a sustained drop in systolic blood pressure <80 mmHg for 218 
more than 10 seconds (24), or b) upon participants request due to the onset of subjective 219 
symptoms (e.g. feelings of dizziness, nausea, faintness). During the Prazosin condition, 220 
participants were unable to last longer than -40mmHg during the LBNP test. For reliable 221 
comparison between the control and drug condition, we chose to only include data until -222 
30mmHg.  223 
 224 
Data analysis 225 
Carotid artery responses. Analyses of diameter (cm), blood flow (ml/sec), blood velocity 226 
(cm/sec) and shear (s
-1
) were performed using custom-designed edge-detection and wall-227 
tracking software, which is largely independent of investigator bias, as was extensively 228 
described elsewhere (4). Baseline diameter, blood flow, blood velocity and shear were 229 
calculated as the mean of data acquired across a 1-minute baseline period (4). For the CPT, 230 
data were calculated for 10-second intervals. LBNP data was calculated per 1-minute 231 
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intervals. Subsequently, offline image analysis involves the identification of the region of 232 
interest (ROI), to allow for automated calibration on the B-mode image and velocities on the 233 
Doppler assessment (40). A ROI is drawn around the optimal B-mode image, in which a 234 
pixel-density algorithm automatically identifies the near- and far wall. Another ROI is drawn 235 
around the Doppler waveform, which is synchronized with the B-mode diameter ROI. 236 
Ultimately, this allows for blood flow and shear rate calculations (40). Peak diameter change 237 
was calculated relative to baseline diameter.  238 
Coronary artery responses. All images were exported for offline analysis using commercially 239 
available software (EchoPAC Version 13.0; GE Medical, Horten, Norway). All 240 
echocardiographic values represent an average value of three cardiac cycles representing the 241 
clearest of five collected images for each experimental stage. The collected waveforms were 242 
analyzed to determine mean diastolic velocity (LADVmean, cm/sec), peak diastolic velocity 243 
(LADVmax, cm/sec), and the velocity time integral (VTI, cm) (19). Coronary flow velocity 244 
reliably reflects changes in absolute coronary blood flow (10, 13, 27), suggesting that an 245 
increase in flow velocity reflects coronary artery dilatation. Using observer-independent 246 
software, VTI is calculated as the integral of individual velocities across the cardiac cycle. 247 
Participants in whom at least 1 image was suboptimal, were excluded prior to analyses (5). 248 
Blood pressure and heart rate. Analyses of systolic and diastolic pressure, heart rate, cardiac 249 
output, stroke volume, and the rate-pressure product (RPP) were performed in commercially 250 
available software (LabChart V7.1, ADInstruments, Colorado Springs, CO, USA). 251 
Measurements were averaged per 10-second bins for analyses for the CPT, and 1-minute bins 252 
for the LBNP analyses. Baseline CPT was averaged over a 3-minute period. Continuous 253 
blood pressure measurements were calibrated to automated brachial blood pressure readings 254 
during baseline (HEM-775CAN, Omron Healthcare, Bannockburn, IL, USA).  255 
 256 
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Statistical analyses 257 
All data were presented as mean±SD unless stated otherwise. Parameters were tested for 258 
normality using a Shapiro-Wilk test. Responses of the CCA (i.e. diameter (cm), blood 259 
velocity (cm/sec), flow (ml/sec) and shear (s
-1
)) and LAD (i.e. mean velocity (cm/sec), max 260 
velocity (cm/sec) and VTI (cm) were assessed during the sympathetic stimulus with paired 261 
Students’ t-tests (in case of non-parametric variables, a Wilcoxon signed-rank test was 262 
performed). Changes over time were assessed with 2-way repeated measurement ANOVA’s 263 
(missing values were only imputed based on previous and consecutive measurements when 264 
available). We assessed whether CCA and LAD changes in diameter, velocity, flow and shear 265 
occurred over time (i.e. within factor ‘time’), and whether this differed between conditions 266 
(i.e. between factor control vs Prazosin) were examined. In addition to the main effects, the 267 
‘time’*’condition’-interaction revealed whether the CCA and LAD changes across time 268 
differed between the control condition and Prazosin. This was done to assess the potential role 269 
of α-receptors in mediating CCA and LAD responses. The 2-way repeated measurement 270 
ANOVA’s were performed with Sidak correction to account for multiple comparisons. Data 271 
were analysed using SPSS 20.0 software (IBM SPSS, IBM Corp., Armonk, NY, USA). 272 
Values for p<0.05 were assumed to be statistical significant. 273 
 274 
 275 
RESULTS 276 
Carotid artery responses: different SNS stimuli. 277 
Cold pressor test. The CPT caused a significant increase in systolic and diastolic blood 278 
pressure and the rate-pressure product (RPP), whilst no change was found in stroke volume, 279 
heart rate and cardiac output (n=9, Table 1). Although the diameter (cm) of the CCA 280 
increased significantly during CPT (P<0.001, Figure 1), CCA velocity (cm/sec), flow (ml/sec) 281 
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and shear rate (s
-1
) did not change significantly across time during CPT (P>0.05, data not 282 
shown).  283 
Lower body negative pressure. LBNP caused a gradual, but significant increase in heart rate, a 284 
decrease in stroke volume and diastolic blood pressure, whilst systolic blood pressure and 285 
cardiac output were preserved (n=9, Table 2). LBNP caused a significant decrease in CCA 286 
diameter (cm, Figure 2), whereas no changes were found in CCA velocity (cm/sec), flow 287 
(ml/sec) and shear (s
-1
) (data not shown).  288 
 289 
Carotid artery response to sympathetic activation: role of α1-receptors. 290 
Cold pressor test. Prazosin increased baseline CCA diameter, and decreased shear ( 291 
0.671±0.05 to 0.703±0.05 cm, and 185.9±50 to 159.1±40 s
-1
 respectively, all P<0.05), whilst 292 
no changes were found in carotid blood flow and blood velocity (10.9±1.8 to 10.8±1.5 ml/sec 293 
P=0.405, and 30.7±6.6 to 27.7±5.2 cm/sec, P=0.051). Prazosin caused an abolished CPT-294 
induced increase in diameter (Figure 3). Prazosin attenuated the increase in blood pressure 295 
during CPT, and resulted in a larger increase in cardiac output, heart rate and RPP during the 296 
CPT (n=9, Table 2). We found no change in stroke volume (Table 2), whilst we also found no 297 
change in CCA flow, shear and velocity (data not shown).  298 
Lower-body negative pressure. Baseline CCA diameter, flow and velocity were significantly 299 
larger following Prazosin adminstration (0.684±0.05 to 0.706±0.05 cm, 10.2±1.6 to 12.0±2.3 300 
ml/sec, and 27.6±5.0 to 30.0±5.5 cm/sec, respectively, all P<0.05). All subjects reached pre-301 
syncope at -30 or -40 mmHg. Therefore, we compared data between both sessions up to -30 302 
mmHg. Prazosin did not alter CCA diameter responses during LBNP (Table 2, Figure 4). 303 
Prazosin exaggerated the increase in heart rate and RPP during LBNP, whilst blood pressure 304 
decreased during the Prazosin trial (n=9, Table 2).  305 
 306 
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Carotid artery responses versus coronary artery responses. 307 
SNS stimulation. Similar to CCA responses, CPT caused a significant increase in LAD 308 
maximum velocity (n=6, baseline 0.25±0.03 to peak 0.34±0.02 cm/sec, P<0.05) and VTI 309 
(P<0.05, Figure 1). Due to the suction of the LBNP box, movement of the participants 310 
prevented assessment in 5 participants. Again in agreement with CCA responses, LBNP 311 
caused a reduction in LAD maximum velocity (n=5, Table 2) and peak VTI (cm, Figure 2). 312 
When pooled, a significant correlation was found between changes in CCA diameter and 313 
LAD peak VTI (n=20, r=0.65, P<0.01).  314 
α1-receptor blockade. Following Prazosin administration, LAD VTI were elevated and 315 
Prazosin abolished the increases in CCA diameter and LAD peak VTI (Figure 3, Table 2). 316 
During LBNP, Prazosin did not alter CCA diameter (cm), LAD peak VTI or LAD peak 317 
velocity responses (cm/sec, up to -30 mmHg; Table 2, Figure 4).  318 
 319 
 320 
DISCUSSION 321 
We present the following findings. First, activation of the SNS using the CPT significantly 322 
increased CCA diameter, whilst SNS activation using LBNP mediated a decrease in CCA 323 
diameter. Second, systemic blockade of the α1-receptors significantly attenuated the dilator 324 
response of the carotid during the CPT, whilst these changes were unaltered during LBNP. 325 
This latter finding suggests the presence of distinct carotid artery responses to different types 326 
of SNS activation, with a distinct contribution of α1-receptors mediating these responses. 327 
Furthermore, we found good agreement between the direction and magnitude of the coronary 328 
and carotid artery responses when comparing the different tests of sympathetic stimulation, 329 
but also regarding the contribution of α1-receptors. Taken together, we found divergent 330 
responses to distinct tests of SNS activation and the role of α1-receptors mediating these 331 
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responses, whilst similarity is found between carotid and coronary arteries in the magnitude 332 
and direction of vascular responses to sympathetic stimulation and blockade of α1-receptors.  333 
 334 
Carotid artery responses to sympathetic stimulation. 335 
The CPT resulted in a characteristic dilation in the CCA of our healthy subjects, a finding 336 
observed previously in our laboratory (44) and others (34). Interestingly, these dilator 337 
responses of the carotid artery contrasts with peripheral artery responses, since brachial or 338 
superficial femoral arteries demonstrate negligible diameter changes during CPT (11, 25). 339 
Central, elastic arteries (such as the carotid artery) may thus respond differently to SNS 340 
activation using the CPT compared to muscular, peripheral arteries. This notion is further 341 
supported by observations of abdominal aorta dilation during the CPT (6). In contrast, LBNP 342 
mediated a decrease in CCA diameter. The presence of distinct artery responses to different 343 
tests of sympathetic activation has also been reported in peripheral conduit arteries (11). Both 344 
CPT and LBNP mediate sympathetic activation through different pathways, leading to distinct 345 
vascular responses in peripheral and central arteries. The CPT causes an immediate stressor 346 
response (11, 27), leading to rapid catecholamine release and blood pressure elevation. This 347 
induces β-receptor mediated vasodilation, and sympathetic blood pressure mediated 348 
constriction, respectively. The resultant of this response is an increase in CCA diameter, due 349 
to the outweighting effect of β-receptor mediated vasodilation. In contrast, the LBNP 350 
mediates a gradual, arterial baroreflex-mediated activation of the sympathetic nervous system 351 
and thus can directly decrease carotid diameter. Both sympathetic tests demonstrate distinct 352 
time-dependent changes in circulating catecholamines, with an immediate elevation after 353 
CPT, and a slower (time- and intensity-dependent) elevation during LBNP (11, 21, 27, 33). 354 
This data indicates that distinct tests of stimulation of the sympathetic nervous system lead to 355 
different carotid artery responses. 356 
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 357 
Role of α1-receptors in carotid artery responses to sympathetic stimulation. 358 
Under physiological conditions, α1-receptors mediate vasoconstriction in coronary arteries 359 
during a sympathetic stimulus (23, 29). Indeed, blockade of α1-receptors resulted in an 360 
increase in baseline CCA diameter and velocity, but also LAD velocity. However, in contrast 361 
to our hypothesis, α1-blockade attenuated the carotid artery dilator responses during the CPT, 362 
whilst no impact of α1-blockade was found during LBNP. One potential explanation is that 363 
the increase in baseline diameter and/or velocity (induced by α1-receptor blockade) prevented 364 
a further increase in diameter upon additional SNS stimulation. This explanation is supported 365 
by previous work in peripheral arteries, which found that an increase in baseline diameter is 366 
associated with a smaller endothelium-(in)dependent vasodilation (37, 39). However, our data 367 
does not reveal such a relation between resting carotid diameter and peak responses (CPT 368 
control r=-0.280, Prazosin r=-0.275, LBNP control r=-0.401, Prazosin r=-0.219, all P>0.05). 369 
Therefore, CCA dilation during α1-blockade may not explain the attenuated vasomotor 370 
responses to CPT or preserved response to LBNP.  371 
 372 
An alternative explanation for the attenuated dilator response may relate to the 373 
pharmacological actions of α1-receptor blockers. In healthy coronary arteries, vasoconstriction 374 
upon sympathetic stimulation is largely mediated via α1-receptors, with only a minor role for 375 
α2-receptors (3, 48). Previous studies in both animals and humans found that during α1-376 
receptor blockade, SNS activation still mediates coronary constriction through activation of 377 
α2-receptors (7, 16, 20). Possibly, α1-receptor blockade in our study yielded stimulation of α2-378 
receptors during activation of the SNS using the CPT. Consequently, the vasodilator 379 
responses may be attenuated by the constrictive actions of α2-receptors. This hypothesis needs 380 
further exploration. A final reason for the diminished CCA dilation during CPT could reside 381 
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in the attenuated blood pressure responses. However, it is unclear whether blood pressure 382 
represents the principal contributor to the carotid dilation, especially since peak diameter 383 
responses precede peak blood pressure values. Moreover, blood pressure rises similarity 384 
between individuals who demonstrate carotid artery vasodilation versus vasoconstriction (44). 385 
Nonetheless, we cannot exclude a potential role for the blood pressure response to contribute 386 
to the carotid dilation.  387 
 388 
Carotid artery versus coronary artery. 389 
Our findings provide strong evidence for similarity between the carotid and coronary arteries 390 
regarding the direction and magnitude of the vasomotor response. Indeed, both carotid and 391 
coronary arteries demonstrated dilation in response to CPT, but constriction was present in 392 
both arteries during LBNP. The presence of coronary dilation to CPT (30, 49), but also 393 
coronary constriction to LBNP (27), has been reported in previous studies. This further 394 
confirms the presence of distinct artery responses to distinct stimuli to activate the 395 
sympathetic nervous system. Furthermore, α1-receptor blockade mediated similar effects 396 
between carotid and coronary arteries for the LBNP test. During the CPT we observed that α1-397 
receptor blockade attenuated the carotid responses, whilst the coronary responses were 398 
reversed. Agreement between arteries was further supported by the presence of a significant 399 
and strong correlation between both arteries (Figure 5), a finding that is in line with previous 400 
work (34, 44). A potential limitation of the echocardiographic measurement is the inability to 401 
examine blood flow. However, strong agreement is present between changes in coronary 402 
artery blood velocity and blood flow in response to sympathetic stimulation (10, 27, 28), 403 
suggesting that the increase in LAD velocity can be interpreted as true coronary vasodilation.  404 
 405 
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Despite these similarities in magnitude and direction of vascular responsiveness, it is 406 
important to emphasise that the mechanisms contributing to vascular control may differ 407 
between arteries. For example, coronary artery flow and velocity during sympathetic 408 
stimulation are dependent on both local metabolic and vasodilatory mechanisms sensitive to 409 
the rate of myocardial oxygen consumption (MVO2).(27) For this purpose, we have calculated 410 
the rate-pressure product, a common used index for myocardial oxygen consumption (RPP, 411 
Figure 6). The increase in RPP during the CPT suggests that the dilation of the coronary 412 
artery is, at least partly, related to the increase in myocardial oxygen uptake. Whether similar 413 
mechanisms are present in the brain to contribute to carotid artery dilation during the CPT is 414 
currently unknown. For the LBNP, we found no important role for RPP to contribute to the 415 
vascular responses in our study. When correcting our responses for potential differences for 416 
the RPP, correlation between LAD VTI and CAR(%) remained present (r=0.66, P<0.05). 417 
Future studies are required to better understand the mechanisms contributing to the vascular 418 
responses during sympathetic stimulation in both carotid and coronary arteries.  419 
 420 
Clinical relevance. Coronary artery responsiveness to SNS stimulation, including the CPT, 421 
has shown a strong predictive ability for future cardiovascular disease and/or events (31, 32, 422 
36). Similarity in vasomotor responsiveness between coronary and carotid arteries suggests 423 
that the carotid artery may serve as a alternative measure for coronary vascular responses to 424 
SNS stimulation. An important advantage of measuring the carotid artery is its easy 425 
accessibility, high reproducibility and the accuracy of the test. This warrants future studies to 426 
further explore the potential clinical use of examining carotid responses to SNS stimulation. 427 
To further explore the similarity between the carotid and coronaries, future studies could be 428 
performed in a catheterisation laboratory, to simultaneously measure both carotid and 429 
coronary artery responses during sympathetic stimulation. These studies can be extended by 430 
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the addition of selective α- and /or β-adrenergic agonist/antagonists, to further resolve the 431 
contribution of adrenergic receptors to sympathetically-mediated carotid and coronary artery 432 
responses.  433 
 434 
Methodological considerations. A strength of our study was that we controlled for end-tidal 435 
gases at baseline values, during both CPT and LBNP, and the α1-receptor blockade condition. 436 
Fluctations and alterations in PETCO2 are known to directly influence the diameter of the CCA 437 
(35) and LAD VTI (5). Following our α1 blockade, which directly affects mean arterial 438 
pressure and ventilatory regulation during sympathetic activation, clamping PETCO2 and 439 
PETO2 to baseline values reduced the possible interference with our carotid and coronary 440 
artery responses.  441 
 442 
To summarize, our data demonstrates that the carotid artery demonstrates distinct vascular 443 
responses to different stimuli to activate the sympathetic nerve system. Additionally, blockade 444 
of the α1-receptors significantly attenuated the dilator responses in the carotid artery during 445 
the CPT, whilst no changes were found during LBNP, suggesting a potential role for α-446 
receptors to contribute to vasomotor responses in carotid arteries. Finally, even though α1-447 
blockade resulted in disparate responses during CPT, our findings indicate strong similarity 448 
between carotid and coronary artery reactivity in response to distinct sympathetic stimuli.  449 
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TABLE 1 – Cold pressor test responses 628 
Cold pressor test  
 
1 minute CPT 2 minutes CPT 3 minutes CPT 
2-way ANOVA 
 
Baseline 10 20 30 40 50 60 70 80  90 100 110 120 130 140 150 160 170 180 Time Trial Time*Trial 
Stroke volume (ml) Control 105±15 106±17 106±16 105±17 105±17 105±19 105±20 105±21 104±20 104±20 103±20 105±21 106±21 106±21 106±20 106±20 106±20 107±19 107±19 
0.450 0.296 0.450 
Stroke volume (ml) Prazosin 112±14 113±15 114±14 114±15 113±16 112±17 111±16 110±15 111±17 111±16 109±17 110±17 110±17 111±17 112±17 111±17 111±18 112±18 112±17 
Cardiac Output (L/min) Control 6.2±1.3 6.6±1.2 6.8±1.3 6.6±1.4 6.7±1.6 6.8±1.8 7.0±1.6 6.9±1.6 6.7±1.7 6.6±1.5 6.3±1.4 6.3±1.5 6.3±1.4 6.3±1.5 6.1±1.6 6.3±1.5 6.3±1.4 6.3±1.5 6.3±1.4 
0.200 0.049 0.021 
Cardiac Output (L/min) Prazosin 6.7±0.9 7.4±1.0 7.5±1.2 7.5±1.3 7.7±1.5 7.7±1.6 7.5±1.6 7.6±1.6 7.5±1.4 7.5±1.4 7.5±1.4 7.6±1.3 7.6±1.2 7.4±1.1 7.6±1.1 7.6±1.1 7.6±1.0 7.7±0.9 7.6±1.0 
Heart Rate (bpm) Control 59±12 63±10 65±11 64±11 64±13 64±12 67±12 66±12 64±13 63±13 62±12 62±13 61±12 61±13 59±15 61±13 61±12 60±14 59±12 
0.107 0.024 0.001 
Heart Rate (bpm) Prazosin 62±12 69±13 68±11 68±11 71±13 71±14 70±13 71±14 70±15 70±14 71±14 72±14 72±14* 70±13 71±13* 71±12 71±13* 71±12* 70±13* 
Diastolic BP (mmHg) Control 79±8 83±6 81±7 84±9 86±8 88±8* 91±8* 92±9* 92±8 92±8 93±9* 92±9* 92±9* 92±9* 91±8* 90±8* 90±8* 90±8 89±8* 
0.000 0.045 0.031 
Diastolic BP (mmHg) Prazosin 74±9 76±9 74±9 76±9 78±9 80±9 81±10 81±9 81±9 82±8* 82±9* 82±8 83±9 80±9 81±9* 82±9* 81±9* 81±9* 80±8* 
Systolic BP (mmHg) Control 133±7 139±8 137±10 140±11 142±12 146±13 148±11* 150±12* 150±12* 150±13 151±13 150±13 151±12 151±11* 150±12* 149±11* 148±10* 148±11 148±11* 
0.000 0.169 0.023 
Systolic BP (mmHg) Prazosin 131±7 136±6* 135±7 136±7 138±6 140±7 141±9 140±7 140±7 140±6 141±8 141±8 141±9 139±9 140±8 141±9* 141±9* 140±9* 140±7* 
Rate pressure product - Control 7927±1754 8787±1449 8963±1654 9028±1804 9160±2048 9483±2096 9901±2047 9978±2093 9619±2114 9549±2097 9458±1931 9253±2024 9212±1982 9166±2045* 8890±2087 9077±2011 8984±1819 8883±2042 8834±1927 
0.008 0.307 0.014 
Rate pressure product - Prazosin 8141±1534 9380±1761 9169±1724 9284±1750 9771±1778 9953±2062 9833±2023 9960±2072 9887±2196 9858±2024 10088±2018 10158±2138 10217±2204 9705±1855 9892±1870* 9941±1667* 9981±1580* 9928±1482* 9826±1709* 
                       
LAD velocity  max Control 0.252±0.03 
  
0.325±0.07 
  
0.304±0.03 
  
0.280±0.05 
  
0.261±0.04 
  
0.266±0.05 
  
0.265±0.05 
0.007 0.769 0.594 
LAD velocity max Prazosin 0.261±0.04 
  
0.312±0.04 
  
0.302±0.07 
  
0.281±0.06 
  
0.278±0.06 
  
0.284±0.06 
  
0.279±0.05 
LAD velocity mean Control 0.201±0.03 
  
0.256±0.07 
  
0.232±0.03 
  
0.224±0.04 
  
0.209±0.03 
  
0.215±0.03 
  
0.207±0.03 
0.041 0.603 0.400 
LAD velocity mean Prazosin 0.199±0.03 
  
0.25±0.02 
  
0.226±0.03 
  
0.228±0.05 
  
0.231±0.04 
  
0.231±0.04 
  
0.228±0.04 
Hemodynamic and coronary responses during Cold pressor test (averaged per 10 second intervals). P-values refer to 2-way repeated measures 629 
ANOVA's, for within participant comparison (time), between trial comparison, and the interaction time*trial. *Symbols denote P<0.05 630 
difference to baseline values.  631 
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TABLE 2 – Lower body negative pressure responses 632 
Lower body negative pressure 
       
2-way ANOVA 
 
Baseline -10 -20 -30 Time Trial Time*Trial 
Stroke volume (ml) Control 106±13 102±12 100±12 97±12 97±13 93±14 90±14 
0.000 0.687 0.086 
Stroke volume (ml) Prazosin 106±12 103±14 99±16 96±15 93±16 91±16 85±18* 
Cardiac Output (L/min) 
Control 6.4±1.2 6.1±1.1 6.1±1.1 5.9±1.1 6.0±1.0 5.8±1.0 5.9±1.0 
0.642 0.002 0.162 
Cardiac Output (L/min) 
Prazosin 7.1±1.4 7.1±1.2 7.2±1.4 7.2±1.0 7.4±0.9 7.5±0.8 7.3±0.9 
Heart Rate (bpm) Control 61±12 60±12 61±13 62±13 63±13 64±14 67±14 
0.000 0.002 0.009 
Heart Rate (bpm) Prazosin 68±16 70±16 75±20 77±17* 82±17* 84±17* 89±17* 
Diastolic BP (mmHg) Control 77±9 77±9 77±9 78±9 78±9 79±9 79±10 
0.177 0.160 0.060 Diastolic BP (mmHg) 
Prazosin 73±8 74±8 72±9 74±8 73±8 74±9 73±9 
Systolic BP (mmHg) Control 132±7 131±6 129±7 130±7 131±6 130±7 131±7 
0.152 0.388 0.005 
Systolic BP (mmHg) Prazosin 131±9 131±9 128±9 129±9 127±10 127±10 124±11 
Rate pressure product - 
Control 
8048±174
6 
7923±174
5 7929±1831 8024±1766 8192±1741 8348±1895 8708±1916 <0.00
1 
0.027 0.025 
Rate pressure product - 
Prazosin 
8954±261
8 
9253±253
7 9646±2963 
9969±2491
* 
10479±2585
* 
10751±2568
* 
10960±2319
* 
           LAD VTI Control 12.1±2.7 11.1±3.6 
 
9.9±3.4 
 
8.7±1.3 
 
0.019 0.09 0.547 
LAD VTI Prazosin 9.5±0.9 9.8±1.9 
 
8.1±2.2 
 
7.8±1.8 
 
LAD velocity  max Control 
0.277±0.0
5 0.26±0.06 
 
0.243±0.05 
 
0.226±0.03 
 
0.029 0.52 0.621 
LAD velocity max Prazosin 0.25±0.06 
0.249±0.0
3 
 
0.226±0.04 
 
0.225±0.04 
 LAD velocity mean Control 0.21±0.03 0.19±0.03 
 
0.203±0.04 
 
0.187±0.03 
 0.496 0.973 0.177 
LAD velocity mean Prazosin 
0.197±0.0
3 
0.207±0.0
2 
 
0.188±0.03 
 
0.20±0.03 
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Hemodynamic and coronary responses during Lower body negative pressure test (averaged per 2 minute stages). P-values refer to 2-way 633 
repeated measures ANOVA's, for within participant comparison (time), between trial comparison, and the interaction time*trial. *Symbols 634 
denote P<0.05 difference to baseline values.635 
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 636 
TABLE 1 – Cold pressor test responses 1 
Cold pressor test   1 minute CPT 2 minutes CPT 3 minutes CPT 
2-way ANOVA 
 Baseline 10 20 30 40 50 60 70 80  90 100 110 120 130 140 150 160 170 180 Time Trial Time*Trial 
Stroke volume (ml) Control 105±15 106±17 106±16 105±17 105±17 105±19 105±20 105±21 104±20 104±20 103±20 105±21 106±21 106±21 106±20 106±20 106±20 107±19 107±19 0.450 0.296 0.450 
Stroke volume (ml) Prazosin 112±14 113±15 114±14 114±15 113±16 112±17 111±16 110±15 111±17 111±16 109±17 110±17 110±17 111±17 112±17 111±17 111±18 112±18 112±17 
Cardiac Output (L/min) Control 6.2±1.3 6.6±1.2 6.8±1.3 6.6±1.4 6.7±1.6 6.8±1.8 7.0±1.6 6.9±1.6 6.7±1.7 6.6±1.5 6.3±1.4 6.3±1.5 6.3±1.4 6.3±1.5 6.1±1.6 6.3±1.5 6.3±1.4 6.3±1.5 6.3±1.4 0.200 0.049 0.021 
Cardiac Output (L/min) Prazosin 6.7±0.9 7.4±1.0 7.5±1.2 7.5±1.3 7.7±1.5 7.7±1.6 7.5±1.6 7.6±1.6 7.5±1.4 7.5±1.4 7.5±1.4 7.6±1.3 7.6±1.2 7.4±1.1 7.6±1.1 7.6±1.1 7.6±1.0 7.7±0.9 7.6±1.0 
Heart Rate (bpm) Control 59±12 63±10 65±11 64±11 64±13 64±12 67±12 66±12 64±13 63±13 62±12 62±13 61±12 61±13 59±15 61±13 61±12 60±14 59±12 0.107 0.024 0.001 
Heart Rate (bpm) Prazosin 62±12 69±13 68±11 68±11 71±13 71±14 70±13 71±14 70±15 70±14 71±14 72±14 72±14* 70±13 71±13* 71±12 71±13* 71±12* 70±13* 
Diastolic BP (mmHg) Control 79±8 83±6 81±7 84±9 86±8 88±8* 91±8* 92±9* 92±8 92±8 93±9* 92±9* 92±9* 92±9* 91±8* 90±8* 90±8* 90±8 89±8* 0.000 0.045 0.031 
Diastolic BP (mmHg) Prazosin 74±9 76±9 74±9 76±9 78±9 80±9 81±10 81±9 81±9 82±8* 82±9* 82±8 83±9 80±9 81±9* 82±9* 81±9* 81±9* 80±8* 
Systolic BP (mmHg) Control 133±7 139±8 137±10 140±11 142±12 146±13 148±11* 150±12* 150±12* 150±13 151±13 150±13 151±12 151±11* 150±12* 149±11* 148±10* 148±11 148±11* 0.000 0.169 0.023 
Systolic BP (mmHg) Prazosin 131±7 136±6* 135±7 136±7 138±6 140±7 141±9 140±7 140±7 140±6 141±8 141±8 141±9 139±9 140±8 141±9* 141±9* 140±9* 140±7* 
Rate pressure product - Control 7927±1754 8787±1449 8963±1654 9028±1804 9160±2048 9483±2096 9901±2047 9978±2093 9619±2114 9549±2097 9458±1931 9253±2024 9212±1982 9166±2045* 8890±2087 9077±2011 8984±1819 8883±2042 8834±1927 0.008 0.307 0.014 
Rate pressure product - Prazosin 8141±1534 9380±1761 9169±1724 9284±1750 9771±1778 9953±2062 9833±2023 9960±2072 9887±2196 9858±2024 10088±2018 10158±2138 10217±2204 9705±1855 9892±1870* 9941±1667* 9981±1580* 9928±1482* 9826±1709* 
                       
LAD velocity  max Control 0.252±0.03   0.325±0.07   0.304±0.03   0.280±0.05   0.261±0.04   0.266±0.05   0.265±0.05 0.007 0.769 0.594 
LAD velocity max Prazosin 0.261±0.04   0.312±0.04   0.302±0.07   0.281±0.06   0.278±0.06   0.284±0.06   0.279±0.05 
LAD velocity mean Control 0.201±0.03   0.256±0.07   0.232±0.03   0.224±0.04   0.209±0.03   0.215±0.03   0.207±0.03 0.041 0.603 0.400 
LAD velocity mean Prazosin 0.199±0.03   0.25±0.02   0.226±0.03   0.228±0.05   0.231±0.04   0.231±0.04   0.228±0.04 
Hemodynamic and coronary responses during Cold pressor test (averaged per 10 second intervals). P-values refer to 2-way repeated measures 2 
ANOVA's, for within participant comparison (time), between trial comparison, and the interaction time*trial. *Symbols denote P<0.05 difference 3 
to baseline values.  4 
TABLE 2 – Lower body negative pressure responses 5 
Lower body negative pressure        2-way ANOVA 
 Baseline -10 -20 -30 Time Trial Time*Trial 
Stroke volume (ml) Control 106±13 102±12 100±12 97±12 97±13 93±14 90±14 0.000 0.687 0.086 
Stroke volume (ml) Prazosin 106±12 103±14 99±16 96±15 93±16 91±16 85±18* 
Cardiac Output (L/min) 
Control 6.4±1.2 6.1±1.1 6.1±1.1 5.9±1.1 6.0±1.0 5.8±1.0 5.9±1.0 0.642 0.002 0.162 
Cardiac Output (L/min) 
Prazosin 7.1±1.4 7.1±1.2 7.2±1.4 7.2±1.0 7.4±0.9 7.5±0.8 7.3±0.9 
Heart Rate (bpm) Control 61±12 60±12 61±13 62±13 63±13 64±14 67±14 0.000 0.002 0.009 
Heart Rate (bpm) Prazosin 68±16 70±16 75±20 77±17* 82±17* 84±17* 89±17* 
Diastolic BP (mmHg) Control 77±9 77±9 77±9 78±9 78±9 79±9 79±10 0.177 0.160 0.060 
Diastolic BP (mmHg) Prazosin 73±8 74±8 72±9 74±8 73±8 74±9 73±9 
Systolic BP (mmHg) Control 132±7 131±6 129±7 130±7 131±6 130±7 131±7 0.152 0.388 0.005 
Systolic BP (mmHg) Prazosin 131±9 131±9 128±9 129±9 127±10 127±10 124±11 
Rate pressure product - 
Control 8048±1746 7923±1745 7929±1831 8024±1766 8192±1741 8348±1895 8708±1916 <0.001 0.027 0.025 
Rate pressure product - 
Prazosin 8954±2618 9253±2537 9646±2963 9969±2491* 10479±2585* 10751±2568* 10960±2319* 
           
LAD VTI Control 12.1±2.7 11.1±3.6  9.9±3.4  8.7±1.3  0.019 0.09 0.547 
LAD VTI Prazosin 9.5±0.9 9.8±1.9  8.1±2.2  7.8±1.8  
LAD velocity  max Control 0.277±0.05 0.26±0.06  0.243±0.05  0.226±0.03  0.029 0.52 0.621 
LAD velocity max Prazosin 0.25±0.06 0.249±0.03  0.226±0.04  0.225±0.04  
LAD velocity mean Control 0.21±0.03 0.19±0.03  0.203±0.04  0.187±0.03  0.496 0.973 0.177 
LAD velocity mean Prazosin 0.197±0.03 0.207±0.02  0.188±0.03  0.20±0.03  
Hemodynamic and coronary responses during Lower body negative pressure test (averaged per 2 minute stages). P-values refer to 2-way repeated 6 
measures ANOVA's, for within participant comparison (time), between trial comparison, and the interaction time*trial. *Symbols denote P<0.05 7 
difference to baseline values.8 
 
FIGURES 1 
 2 
FIGURE 1. Responses of the carotid artery (n=9) and the LAD coronary artery (n=6) to CPT. 3 
A. Diameter change of the carotid artery over time. B. Percentage change in carotid diameter 4 
at baseline and during CPT (area under the curve, AUC). C. VTI change of the LAD coronary 5 
artery over time. D. Percentage change in LAD coronary artery VTI at baseline and during CPT 6 
(area under the curve, AUC). Data are presented as mean, error bars represent standard error of 7 
the mean (SEM). White bars represent baseline measurements, black bars represent peak 8 
values. 9 
 10 
FIGURE 2. Responses of the carotid artery (n=9) and the LAD coronary artery (n=5) to LBNP. 11 
A. The diameter change of the carotid artery over time. B. The percentage change in carotid 12 
diameter at baseline and during LBNP. C. the VTI change of the LAD coronary artery over 13 
time. D. The percentage change in LAD coronary artery VTI at baseline and during LBNP. 14 
Data are presented as mean, error bars represent standard error of the mean (SEM). White bars 15 
represent baseline measurements, black bars represent peak values. 16 
 17 
FIGURE 3. Responses of the carotid artery (n=9) and the LAD coronary artery (n=6) to CPT, 18 
Control versus Prazosin condition. A. Diameter change of the carotid artery over time. B. 19 
Percentage change in diameter. C. VTI change of the LAD coronary artery over time. D.  20 
Percentage change in LAD coronary artery VTI at baseline and during the CPT. Data are 21 
presented as mean, error bars represent standard error of the mean (SEM). White bars represent 22 
the Control condition, black bars represent the Prazosin condition.   23 
 24 
FIGURE 4. Responses of the carotid artery (n=9) and the LAD coronary artery (n=5) to LBNP, 25 
Control versus Prazosin condition. A. Diameter change of the carotid artery over time. B. 26 
Percentage change in carotid diameter at baseline and during the LBNP. C. VTI change of the 27 
LAD coronary artery over time. D. Percentage change in LAD coronary artery VTI at baseline 28 
and during the LBNP. Data are presented as mean, error bars represent standard error of the 29 
mean (SEM). White bars represent the Control condition, black bars represent the Prazosin 30 
condition. 31 
 32 
FIGURE 5. Correlation between the carotid artery diameter response (CAR%) and coronary 33 
LAD response (change in the velocity time integral (VTI in cm)) pooled for the cold pressor 34 
test and lower body negative pressure test (n=16).  35 
 36 
FIGURE 6. Mean coronary velocity expressed versus the rate pressure product (RPP). A. 37 
Responses of mean coronary velocity versus RPP during CPT. B. Responses of mean coronary 38 
velocity versus RPP during CPT with prazosin. C. Responses of mean coronary velocity versus 39 
RPP during LBNP. D. Responses of mean coronary velocity versus RPP during LBNP with 40 
prazosin. Light grey indicates individual responses, whilst the black arrows indicate the mean 41 
response.   42 
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